Shares of Amarin Co. plc (NASDAQ:AMRN - Get Free Report) crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $10.40 and traded as high as $11.20. Amarin shares last traded at $11.18, with a volume of 77,915 shares changing hands.
Wall Street Analyst Weigh In
A number of equities research analysts have recently issued reports on the stock. StockNews.com initiated coverage on shares of Amarin in a report on Wednesday, April 16th. They set a "sell" rating for the company. The Goldman Sachs Group decreased their price target on shares of Amarin from $20.00 to $7.00 and set a "sell" rating for the company in a research note on Thursday, April 17th.
Check Out Our Latest Report on Amarin
Amarin Trading Down 6.7 %
The company has a market capitalization of $214.17 million, a PE ratio of -115.89 and a beta of 1.38. The business's 50-day simple moving average is $9.62 and its two-hundred day simple moving average is $10.37.
Amarin (NASDAQ:AMRN - Get Free Report) last issued its quarterly earnings results on Wednesday, March 12th. The biopharmaceutical company reported ($2.40) EPS for the quarter, missing the consensus estimate of ($1.20) by ($1.20). Amarin had a negative return on equity of 7.22% and a negative net margin of 16.33%. The business had revenue of $62.31 million during the quarter, compared to the consensus estimate of $32.37 million. On average, analysts forecast that Amarin Co. plc will post -0.15 EPS for the current year.
Institutional Trading of Amarin
A number of institutional investors and hedge funds have recently added to or reduced their stakes in AMRN. Waterfront Wealth Inc. boosted its holdings in Amarin by 181.4% in the fourth quarter. Waterfront Wealth Inc. now owns 2,481,766 shares of the biopharmaceutical company's stock valued at $1,204,000 after acquiring an additional 1,599,956 shares during the last quarter. AXA S.A. bought a new stake in Amarin in the 4th quarter valued at approximately $480,000. Raymond James Financial Inc. bought a new position in Amarin in the fourth quarter valued at $343,000. Quinn Opportunity Partners LLC raised its holdings in Amarin by 85.2% during the fourth quarter. Quinn Opportunity Partners LLC now owns 1,106,539 shares of the biopharmaceutical company's stock worth $537,000 after acquiring an additional 508,989 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV acquired a new position in Amarin during the fourth quarter worth $171,000. Institutional investors own 22.25% of the company's stock.
About Amarin
(
Get Free Report)
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Further Reading
Before you consider Amarin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amarin wasn't on the list.
While Amarin currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
